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Background:  The risk of stroke in patients with atrial fibrillation (AF) is influenced by co-morbidities. We evaluated the impact of the novel 
CHA2DS2-VASc risk score on outcomes in 18,113 AF patients randomized to dabigatran 110 mg (D110), dabigatran 150 mg (D150) or warfarin.
Methods:  The CHA2DS2-VAsc score assigns 1 point for each of heart failure, hypertension, age 65-74, diabetes, females, vascular disease and 2 
points for stroke/TIA and age ≥75. We calculated relative risks (RR), 95 % confidence intervals and p-values for interaction.
Results:  Distribution of CHA2DS2-VASc scores were 0-2 (n=4,042); 3 (n=5,365); 4 (n=4,374) or 5-9 (n=4,327). *The net clinical benefit was 
stroke, systemic embolism, pulmonary embolism, myocardial infarction, all-cause death and major bleeding.
Conclusion: D150 was superior to warfarin and D110 non-inferior to warfarin for stroke prevention irrespective of CHA2DS2-Vasc scores. Both 
dabigatran doses have a favorable benefit risk profile compared to warfarin in patients with lower CHA2DS2-Vasc scores.
D110 D150 Warfarin D110 vs. Warfarin D150 vs. Warfarin
annual rate annual rate annual rate RR 95%CI P (Int) RR 95% CI P (Int)
Primary outcome  
Stroke/syst embolism
0.82 0.60
CHA2DS2-VASc = 0-2 0.9% 0.5% 0.8% 1.08 0.60 1.95 0.63 0.32 1.23
CHA2DS2-VASc = 3 1.3% 0.8% 1.4% 0.99 0.67 1.48 0.61 0.38 0.96
CHA2DS2-VASc = 4 1.6% 1.0% 2.0% 0.81 0.55 1.20 0.53 0.34 0.82
CHA2DS2-VASc = 5-9 2.4% 2.1% 2.8% 0.85 0.62 1.19 0.77 0.55 1.07
Major bleed 0.06 0.003
CHA2DS2-VASc = 0-2 1.3% 1.8% 2.4% 0.55 0.37 0.83 0.75 0.52 1.08
CHA2DS2-VASc = 3 2.5% 2.6% 3.5% 0.70 0.54 0.92 0.74 0.56 0.97
CHA2DS2-VASc = 4 3.3% 3.2% 3.9% 0.86 0.65 1.13 0.83 0.63 1.09
CHA2DS2-VASc = 5-9 4.4% 5.8% 4.4% 1.00 0.77 1.28 1.33 1.06 1.69
Net clinical benefit* 0.27 0.01
CHA2DS2-VASc = 0-2 4.2% 4.2% 5.2% 0.80 0.62 1.02 0.81 0.63 1.03
CHA2DS2-VASc = 3 6.3% 5.6% 7.2% 0.88 0.73 1.05 0.77 0.64 0.93
CHA2DS2-VASc = 4 9.0% 7.1% 8.5% 1.06 0.89 1.26 0.83 0.69 1.00
CHA2DS2-VASc = 5-9 10.0% 11.9% 10.8% 0.92 0.78 1.08 1.11 0.95 1.30
